Peptide Initiative

Peptides · Peptide comparison

Pancragen vs Xenin-25

Tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that binds ACCT sequences in pancreatic gene promoters with 3-fold greater affinity than related peptides, stimulates beta-cell differentiation through Pdx1/Pax6/NGN3 transcription factor activation, and corrects impaired glucose tolerance in primates more physiologically than glimepiride

The Natural Incretin Helper Peptide That Enhances Glucose Control and Insulin Response

  • Metabolic
  • Metabolic

At a glance

Quick comparison

Dose rangePancragen500–500 mcgXenin-254–4 pmol/kg/min
FrequencyPancragenMultiple times dailyXenin-25Once daily
AdministrationPancragenIntramuscular injectionXenin-25Intravenous (IV)
Cycle lengthPancragen8-12 weeksXenin-25Ongoing/indefinite
Onset speedPancragenGradual (3-4 weeks)Xenin-25Moderate (1-2 weeks)
Evidence levelPancragenLimited human trialsXenin-25Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Blood Sugar Balance

Pancragen92%
Xenin-25No recorded rating

Pancreas Protection

Pancragen88%
Xenin-25No recorded rating

Metabolic Aging Support

Pancragen85%
Xenin-25No recorded rating

Glucose Control & Insulin Response

PancragenNo recorded rating
Xenin-2592%

Metabolic Synergy

PancragenNo recorded rating
Xenin-2585%

Natural Physiological Action

PancragenNo recorded rating
Xenin-2580%

Technical data

Compound specifications

Pancragen

Molecular formula
C26H36N6O9
Molecular weight
576.6 g/mol
Half-life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids
Bioavailability
Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses
CAS number
Not definitively assigned

Xenin-25

Molecular formula
C139H224N38O32S
Molecular weight
2971.6 g/mol
Half-life
10-15 minutes (IV administration, subject to variation)
Bioavailability
IV: ~100%; Subcutaneous: Research-dependent; Oral: Limited due to peptide nature (active research)
CAS number
Not available

Protocols

Dosing compared

Pancragen

Oral

  • 500 mcgTwice daily (morning and evening) · 4-week courseDocumented oral dose for the Pankragen-Forte capsule: 500 mcg twice daily for 4 weeks in elderly patients with a prediabetic state [3]. The intramuscular route appears only in animal studies with no published human dose, so it is not listed here.

Xenin-25

Intravenous infusion

  • 4 pmol/kg/min (after a brief higher loading ramp of 10.8→7.7→5.6 pmol/kg/min over the first 10 min)Continuous infusion · Up to ~4 hours (during glucose clamp)Human IV infusion dose used to amplify GIP-mediated insulin secretion during a hyperglycemic clamp [5]. Research use only.

Applications

Best suited for

Pancragen

Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting metabolic aging
Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Xenin-25

Supporting healthy glucose metabolism
Xenin-25 is particularly well-suited for individuals focused on supporting healthy glucose metabolism. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing insulin response efficiency
Xenin-25 is particularly well-suited for individuals focused on enhancing insulin response efficiency. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Research into metabolic disorder treatment
Xenin-25 is particularly well-suited for individuals focused on research into metabolic disorder treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Pancragen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Minor digestive changes

Uncommon

  • Mild hypoglycemia

Serious

  • No documented serious adverse effects

Xenin-25

Common

  • Gastrointestinal Discomfort
  • Nausea
  • Headache

Uncommon

  • Injection Site Reactions
  • Mild Fatigue

Serious

  • Hypoglycemia Risk

Research status

Safety & evidence

Pancragen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
  • Concurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects

Xenin-25

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Xenin-25 is a 25-amino acid natural gut peptide discovered in 1992 with moderate evidence from Phase 1-2 human clinical trials. The peptide has been extensively studied in metabolic research for over 30 years. Safety profile shows good tolerability in research settings with mild, transient gastrointestinal effects being the most common. Critical limitation: Xenin-25 has NOT completed Phase 3 clinical trials and is not FDA-approved for clinical use. No serious adverse effects have been reported in research studies, but hypoglycemia risk requires careful monitoring when combined with insulin or other glucose-lowering agents. Individual responses to Xenin-25 are generally mild gastrointestinal discomfort, nausea, or headache in the first few days—these typically resolve with continued use. The peptide's glucose-dependent mechanism makes hypoglycemia unlikely when used alone, but additive effects with other agents require medical supervision.

Contraindications

  • Pregnancy and breastfeeding
  • Severe kidney or liver disease

Decision guide

Which is right for you?

Pancragen

Choose Pancragen if…

  • Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
  • Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
  • Comprehensive Khavinson bioregulator protocols targeting metabolic aging
  • Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance

Xenin-25

Choose Xenin-25 if…

  • Supporting healthy glucose metabolism
  • Enhancing insulin response efficiency
  • Research into metabolic disorder treatment